Case Report

Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis

Swetha Tatineni,1 Zachary Warren,2 Mark A. Applebaum,3 and Fuad M. Baroody2,3

1Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA
2Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, The University of Chicago, Chicago, Illinois, USA
3Department of Pediatrics, The University of Chicago, Chicago, Illinois, USA

Correspondence should be addressed to Fuad M. Baroody; fbaroody@surgery.bsd.uchicago.edu

Received 16 July 2022; Revised 20 October 2022; Accepted 10 November 2022; Published 29 November 2022

Copyright © 2022 Swetha Tatineni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recurrent respiratory papillomatosis (RRP) is the most common benign pediatric laryngeal neoplasm. Various adjuvant medical therapies have failed to reliably decrease surgical frequency in this challenging airway disease. Recently, systemic bevacizumab has shown promise in advanced, treatment-resistant papillomatosis. We describe the use of systemic bevacizumab in two children with severe RRP unresponsive to other therapies. Voice and breathing improved dramatically in both patients with minimal side effects. Both patients have not required surgery in 24 months and 16 months, respectively. Systemic bevacizumab is a promising long-term treatment for severe RRP, with oncology playing an important role in patient care.

1. Introduction

Recurrent respiratory papillomatosis (RRP), the most common benign pediatric laryngeal neoplasm, is caused by human papillomavirus (HPV) and characterized by recurrent proliferation of squamous papillomas within the airway [1]. Age at diagnosis <5 years is associated with aggressive disease, resulting in persistent voice disturbance and airway obstruction [2]. There is no cure, and surgery remains the standard of care, though up to 20% of patients require adjuvant medical therapy from having more than four surgeries per year, airway compromise, or distal multisite spread of disease [1].

Bevacizumab (Avastin, Genentech) and its biosimilar bevacizumab-awwb (Mvasi, Amgen) are recombinant humanized monoclonal antibodies that target vascular endothelial growth factor (VEGF) to inhibit angiogenesis. Despite the well-established efficacy in adult oncology, bevacizumab use remains limited in pediatrics [3, 4]. Intralesional bevacizumab injections have limited efficacy in multifocal RRP [5–8]. Recently, systemic bevacizumab has shown promise in advanced, treatment-resistant papillomatosis [8–13]. Here, we describe the long-term use of IV bevacizumab for severe RRP affecting two children.

2. Case 1

An 8-year-old boy was diagnosed with RRP (HPV serotype 6) at 22 months and required 26 surgeries by age six. He failed adjuvant therapies, including recombinant HPV vaccine (types 6, 11, 16, and 18) and nineteen intralesional bevacizumab injections. Systemic bevacizumab-awwb treatment was planned under pediatric oncology supervision. Pretreatment direct laryngoscopy showed extensive papillomas along the epiglottis, bilateral aryepiglottic folds, and bilateral true and false cords with subglottic extension (Figure 1(a)). Trachea was spared, and chest CT showed no pulmonary disease. In June 2020, the patient underwent his first bevacizumab-awwb infusion of 10 mg/kg, ultimately receiving four treatments at three-week intervals. After the first treatment, the patient had significant improvement in voice. Direct laryngoscopy after the third treatment showed few small papillomas on the laryngeal surface of the epiglottis (Figure 1(a)). After the fourth treatment, infusions were spaced by three additional weeks after each set of three treatments. The only side effect was mild stomachache that resolved after the first treatment. As of June 2022, the patient completed his final 12-week interval treatment and remains asymptomatic with last surgery in
frequency. Bevacizumab targets VEGF to inhibit angiogenesis, papilloma burden [8].

Intralesional bevacizumab, have failed to consistently decrease treatments in their lifetime, posing emotional and financial costs to patients and their families [15, 16]. Many adjuvant therapies, including interferonalfa, intralesional cidofovir, and intralesional bevacizumab, have failed to consistently decrease papilloma burden [8].

Systemic bevacizumab has been shown to reduce surgical frequency. Bevacizumab targets VEGF to inhibit angiogenesis, indirectly inhibiting papilloma growth. Papilloma epithelium and underlying vascular endothelium show strong expression of VEGF and VEGFR-1 and VEGFR-2, respectively [17]. However, underlying viral infection is unaffected, and recurrence after stopping bevacizumab is possible [9, 11, 18].

We present two children who continue to receive systemic bevacizumab-awwb, which is structurally, functionally, and clinically similar to bevacizumab [19]. Both patients received identical infusion schedules with a follow-up of 24 months and 16 months, respectively. Immediate improvement in respiratory and vocal symptoms was observed after just one treatment. Normal vocal quality often correlates with significant reduction of laryngeal lesions which was observed [13]. Both patients have remained asymptomatic with increasing treatment intervals, with the longest current interval being 16 weeks between treatments. The only side effects observed were trace self-resolving proteinuria and stomachache, consistent with prior studies demonstrating good tolerability of bevacizumab among children [4].

A recent international consensus statement for systemic bevacizumab use in RRP proposed that multiple disciplines, including pediatric oncology, are necessary, highlighting a novel treatment paradigm for this benign but aggressive airway tumor [20]. Long-term effects and appropriate dosing schedules, including treatment endpoint, are unknown. Anecdotal evidence suggests spacing treatments as detailed above. If symptoms recur, treatment frequency can be increased. Accumulated clinical experience through multidisciplinary partnerships may facilitate efforts to standardize bevacizumab administration. A national registry of patients detailing treatment schedules and response is essential to inform future therapeutic decisions and clinical trials.

**Abbreviations**

RRP: Recurrent respiratory papillomatosis
HPV: Human papillomavirus
VEGF: Vascular endothelial growth factor
VEGFR: Vascular endothelial growth factor receptor.

**Data Availability**

Data are available upon request or included within the article.
Conflicts of Interest
Authors have no conflicts of interest to disclose.

References
[1] C. S. Derkay and A. E. Bluher, “Update on recurrent respiratory papillomatosis,” Otolaryngologic Clinics of North America, vol. 52, no. 4, pp. 669–679, 2019.
[2] F. J. Buchinsky, W. L. Valentino, N. Ruszkay et al., “Age at diagnosis, but not HPV type, is strongly associated with clinical course in recurrent respiratory papillomatosis,” PLoS One, vol. 14, no. 6, article e0216697, 2019.
[3] J. Garcia, H. I. Hurwitz, A. B. Sandler et al., “Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook,” Cancer Treatment Reviews, vol. 86, article 102017, 2020.
[4] A. Barone and J. B. Rubin, “Opportunities and challenges for successful use of bevacizumab in pediatrics,” Oncologia, vol. 3, p. 92, 2013.
[5] D. R. Sidell, M. Nassar, R. T. Cotton, S. M. Zeitels, and A. de Alarcon, “High-dose sublesional bevacizumab (Avastin) for pediatric recurrent respiratory papillomatosis,” The Annals of Otology, Rhinology, and Laryngology, vol. 123, no. 3, pp. 214–221, 2014.
[6] S. M. Zeitels, G. Lopez-Guerra, J. A. Burns, M. Lutch, A. M. Friedman, and R. E. Hillman, “Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis,” The Annals of Otology, Rhinology & Laryngology. Supplement, vol. 201, pp. 1–13, 2009.
[7] D. J. Rogers, S. Ojha, R. Maurer, and C. J. Hartnick, “Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children,” JAMA Otolaryngology. Head & Neck Surgery, vol. 139, no. 5, pp. 496–501, 2013.
[8] S. R. Best, M. Mohr, and K. B. Zur, “Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey,” The Laryngoscope, vol. 127, no. 10, pp. 2225–2227, 2017.
[9] M. Mohr, C. Schliemann, C. Biermann et al., “Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis,” Oncology Letters, vol. 8, no. 5, pp. 1912–1918, 2014.
[10] K. B. Zur and E. Fox, “Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child,” The Laryngoscope, vol. 127, no. 7, pp. 1538–1542, 2017.
[11] C. Carnevale, L. Ferrán-De la Cierva, G. Til-Pérez et al., “Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children,” The Laryngoscope, vol. 129, no. 4, pp. 1001–1004, 2019.
[12] O. Hamdi, J. Dome, G. Zal zal, and D. Preciado, “Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: a case report,” International Journal of Pediatric Otorhinolaryngology, vol. 128, article 109706, 2020.
[13] R. Ruiz, N. Balamuth, L. R. Javia, and K. B. Zur, “Systemic bevacizumab treatment for recurrent respiratory papillomatosis: long- term follow-up,” The Laryngoscope, vol. 132, no. 10.1002/lary.30021, pp. 2071–2075, 2022.
[14] J. J. Benedict and C. S. Derkay, “Recurrence respiratory papillomatosis: a 2020 perspective,” Laryngoscope Investig Otolaryngol, vol. 6, no. 2, pp. 340–345, 2021.
[15] M. Krstić, J. Pavlović, P. Stanković, and T. Milenković, “Etiopathogenesis of recurrent laryngeal papillomatosis and contemporary treatment strategies,” Acta medica Medianae, vol. 53, no. 4, pp. 64–74, 2014.
[16] L. Pogoda, F. Ziyalan, D. P. J. Smeeing, F. G. Dikkers, and R. N. P. M. Rinkel, “Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review,” European Archives of Oto-Rhino-Laryngology, vol. 279, no. 9, pp. 4229–4240, 2022.
[17] R. Rahbar, S. O. Vargas, J. Folkman et al., “Role of vascular endothelial growth factor-a in recurrent respiratory papillomatosis,” The Annals of Otology, Rhinology, and Laryngology, vol. 114, no. 4, pp. 289–295, 2005.
[18] O. H. Enrique, S. H. Eloy, T. P. Adrian, and V. Perla, “Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: a series of three pediatric cases and literature review,” American Journal of Otolaryngology, vol. 42, no. 5, article 103126, 2021.
[19] M. Thomas, N. Thatcher, J. Goldschmidt, Y. Ohe, H. J. McBride, and V. Hanes, “Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar,” Immunotherapy, vol. 11, no. 15, pp. 1337–1351, 2019.
[20] D. R. Sidell, K. Balakrishnan, S. R. Best et al., “Systemic bevacizumab for treatment of respiratory papillomatosis: international consensus statement,” The Laryngoscope, vol. 131, no. 6, pp. E1941–E1949, 2021.